Exposure-adjusted event rates, E (E/100 PY) | Any upadacitinib 15 mg QDa (n = 414; PY = 534.4) |
---|---|
Any AE | 877 (164.1) |
Serious AE | 53 (9.9) |
AE leading to discontinuation of study drug | 16 (3.0) |
Any COVID-19-related AE | 81 (15.2) |
Any deathb | 1 (0.2) |
Infection | 301 (56.3) |
Serious infection | 24 (4.5) |
Opportunistic infectionc | 0 |
Herpes zosterd | 19 (3.6) |
Active tuberculosis | 0 |
Malignancy other than NMSCe | 1 (0.2) |
NMSC | 2 (0.4) |
Adjudicated MACEf | 1 (0.2) |
Adjudicated VTEg | 2 (0.4) |
Adjudicated gastrointestinal perforation | 0 |
Renal dysfunctionh | 1 (0.2) |
Anemia | 11 (2.1) |
Lymphopenia | 3 (0.6) |
Neutropenia | 19 (3.6) |
Hepatic disorder | 47 (8.8) |
Uveitisi | 7 (1.3) |
Inflammatory bowel diseasej | 1 (0.2) |
Psoriasis | 2 (0.4) |